Summary & Overview
CPT 90377: Human Rabies Immunoglobulin, High-Titer
CPT code 90377 represents human rabies immunoglobulin (high-titer) — a pooled plasma-derived gamma globulin used to provide immediate passive immunity for category III rabies exposures. Nationally, timely administration of rabies immunoglobulin is critical for preventing rabies infection after high-risk exposures and is an essential element of post-exposure prophylaxis alongside rabies vaccine.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of 90377, typical sites of service where the product is administered, and the operational considerations that affect billing and coverage across major payers. The publication summarizes common coding and billing practice themes for biologic immunoglobulin products, reimbursement benchmarks where available, and payer policy patterns relevant to authorization and administration requirements.
This summary provides clinicians, billing professionals, and policy analysts with the clinical framing and payer landscape for rabies immunoglobulin coded with 90377, helping stakeholders understand where this service fits within post-exposure care and payer coverage considerations at a national level.
Billing Code Overview
CPT code 90377 describes rabies immunoglobulin (human), derived from pooled human plasma, high-titer used to provide passive immunity for prevention or treatment of category III rabies exposures. These products supply ready-made antibodies to neutralize rabies virus and are administered as part of post-exposure prophylaxis when immediate passive immunization is required.
Service Type: Immune globulin product administration for rabies post-exposure prophylaxis
Typical Site of Service: Hospital outpatient department, emergency department, clinic, or other acute care settings where post-exposure prophylaxis is provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a person with a category III potential rabies exposure (e.g., single or multiple transdermal bites or scratches, contamination of mucous membrane with saliva from a rabid or suspect animal). The patient presents to the emergency department, urgent care, or public health clinic within hours of exposure. Clinical workflow: triage assessment of wound and exposure type; wound cleaning and local care; determination of rabies prophylaxis need; administration of rabies immunoglobulin (90377) infiltrated into and around the wound site with any remaining volume given intramuscularly, concurrently with initiation of rabies vaccine series. Documentation includes exposure details (animal type, provoked vs unprovoked), wound description, informed consent, lot numbers and amounts of 90377 administered, concurrent vaccine doses, and patient education and follow-up for vaccine schedule. Typical sites of service are Emergency Department, Urgent Care, Hospital Outpatient Clinic, and Public Health Clinic.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier – standard reporting | Use when no special circumstances or modifiers apply to the administration of 90377. |